BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12098067)

  • 1. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation.
    Altès A; Remacha AF; Sureda A; Martino R; Briones J; Canals C; Brunet S; Sierra J; Gimferrer E
    Bone Marrow Transplant; 2002 Jun; 29(12):987-9. PubMed ID: 12098067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
    Kim YR; Kim JS; Cheong JW; Song JW; Min YH
    Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic myeloablative transplantation for patients aged 50 years and over.
    Yanada M; Emi N; Naoe T; Sakamaki H; Iseki T; Hirabayashi N; Karasuno T; Chiba S; Atsuta Y; Hamajima N; Takahashi S; Kato S
    Bone Marrow Transplant; 2004 Jul; 34(1):29-35. PubMed ID: 15156161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
    Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation.
    Sucak GT; Yegin ZA; Ozkurt ZN; Aki SZ; Yağci M
    Transplant Proc; 2010 Jun; 42(5):1841-8. PubMed ID: 20620535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clinical impact of iron overload in stem cell transplantation. A prospective study.
    Altes A; Remacha AF; Sarda P; Baiget M; Sureda A; Martino R; Briones J; Brunet S; Canals C; Sierra J
    Ann Hematol; 2007 Jun; 86(6):443-7. PubMed ID: 17279415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
    Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
    Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma.
    Mahindra A; Bolwell B; Sobecks R; Rybicki L; Pohlman B; Dean R; Andresen S; Sweetenham J; Kalaycio M; Copelan E
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1239-44. PubMed ID: 18940678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.
    Pullarkat V; Blanchard S; Tegtmeier B; Dagis A; Patane K; Ito J; Forman SJ
    Bone Marrow Transplant; 2008 Dec; 42(12):799-805. PubMed ID: 18762767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation.
    Dadwal SS; Tegtmeier B; Liu X; Frankel P; Ito J; Forman SJ; Pullarkat V
    Eur J Haematol; 2015 Mar; 94(3):235-42. PubMed ID: 25082161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation.
    Mahindra A; Bolwell B; Sobecks R; Rybicki L; Pohlman B; Dean R; Andresen S; Sweetenham J; Kalaycio M; Copelan E
    Br J Haematol; 2009 Aug; 146(3):310-6. PubMed ID: 19508292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Villela L; Sureda A; Canals C; Sanz MA; Martino R; Valcárcel D; Altés A; Briones J; Gómez M; Brunet S; Sierra J
    Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.